GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gubra AS (FRA:PI3) » Definitions » Tax Provision

Gubra AS (FRA:PI3) Tax Provision : €0.79 Mil (TTM As of Dec. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Gubra AS Tax Provision?

Gubra AS's tax provision for the six months ended in Dec. 2024 was €0.79 Mil. Its tax provision for the trailing twelve months (TTM) ended in Dec. 2024 was €0.79 Mil.


Gubra AS Tax Provision Historical Data

The historical data trend for Gubra AS's Tax Provision can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gubra AS Tax Provision Chart

Gubra AS Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Tax Provision
Get a 7-Day Free Trial -0.13 -2.58 -0.26 -0.22 0.79

Gubra AS Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Tax Provision Get a 7-Day Free Trial -0.68 0.67 -0.89 - 0.79

Gubra AS Tax Provision Calculation

Tax to be paid.

Tax Provision for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.79 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Gubra AS Business Description

Traded in Other Exchanges
Address
Horsholm Kongevej 11B, Horsholm, DNK, 2970
Gubra AS is a specialized preclinical CRO and biotech company focused on peptide-based drug discovery within metabolic and fibrotic diseases. The company has three segments: Pre-clinical contract research (CRO), which derives maximum revenue; Discovery & Partnerships (D&P) Segment; and Gubra Green Segment.

Gubra AS Headlines

No Headlines